Literature DB >> 28632250

Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities.

Susan Storey1, Diane Von Ah, Marilyn J Hammer2.   

Abstract

PROBLEM IDENTIFICATION: Poor health outcomes have been associated with hyperglycemia in patients with and without diabetes. However, the impact of hyperglycemia on the health-related outcomes of patients with cancer has shown conflicting results. The purpose of this review was to explore definitions and measurement issues related to the assessment of hyperglycemia and the subsequent impact on the findings of health-related outcomes in adults with cancer.
. LITERATURE SEARCH: Four electronic databases were searched. DATA EVALUATION: A total of 30 articles were reviewed. Quantitative articles were synthesized using integrative review strategies. 
. SYNTHESIS: Three key gaps were identified in the literature.
CONCLUSIONS: This review highlights the inconsistencies in measuring or assessing hyperglycemia and the lack of standardized guidelines in treating hyperglycemia. Failure to have a standard approach to the measurement and management of hyperglycemia impedes the ability of healthcare providers to determine the significance of its impact on health outcomes. Further research is needed to establish appropriate measurement guidelines to address hyperglycemia in people with cancer.
. IMPLICATIONS FOR PRACTICE: Evidence-based measurement and treatment guidelines are needed to inform and assist healthcare providers with clinical decision making for people with cancer who experience hyperglycemia.

Entities:  

Keywords:  cancer
; glucose measurement; health outcomes; hyperglycemia

Mesh:

Substances:

Year:  2017        PMID: 28632250      PMCID: PMC5831080          DOI: 10.1188/17.ONF.E141-E151

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  61 in total

Review 1.  The impact of hyperglycemia on hematopoietic cell transplantation outcomes: an integrative review.

Authors:  Jill M Olausson; Marilyn J Hammer; Veronica Brady
Journal:  Oncol Nurs Forum       Date:  2014-09       Impact factor: 2.172

Review 2.  Diabetology and oncology meet in a network model: union is strength.

Authors:  Marco Gallo; Luigi Gentile; Emanuela Arvat; Oscar Bertetto; Gennaro Clemente
Journal:  Acta Diabetol       Date:  2016-02-10       Impact factor: 4.280

3.  High mortality associated with hyperglycemia, neutrophilia, and lymphopenia in critically ill patients.

Authors:  Enrique O Jiménez-Ibáñez; Manuel Castillejos-López; Andrés Hernández; Patricia Gorocica; Noé Alvarado-Vásquez
Journal:  Tohoku J Exp Med       Date:  2012-03       Impact factor: 1.848

4.  Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes.

Authors:  Joseph Pidala; Jongphil Kim; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Teresa Field; Janelle Perkins; Lia Perez; Hugo Fernandez; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-15       Impact factor: 5.742

5.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

6.  The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients.

Authors:  Marilyn J Hammer; Corey Casper; Ted A Gooley; Paul V O'Donnell; Michael Boeckh; Irl B Hirsch
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

7.  Impact of Hyperglycemia and Age on Outcomes in Patients With Acute Myeloid Leukemia.

Authors:  Susan Storey; Diane Von Ah
Journal:  Oncol Nurs Forum       Date:  2016-09-01       Impact factor: 2.172

8.  Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.

Authors:  Mary Ann Weiser; Maria E Cabanillas; Marina Konopleva; Deborah A Thomas; Sherry A Pierce; Carmen P Escalante; Hagop M Kantarjian; Susan M O'Brien
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

9.  Glucose variability is associated with intensive care unit mortality.

Authors:  Jeroen Hermanides; Titia M Vriesendorp; Robert J Bosman; Durk F Zandstra; Joost B Hoekstra; J Hans Devries
Journal:  Crit Care Med       Date:  2010-03       Impact factor: 7.598

10.  Modeling of hypo/hyperglycemia and their impact on breast cancer progression related molecules.

Authors:  Sirin A I Adham; Hasina Al Rawahi; Sumaya Habib; Mansour S Al Moundhri; Alicia Viloria-Petit; Brenda L Coomber
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

View more
  3 in total

1.  Effect of Average Blood Glucose Greater Than 140 mg/dL on Adverse Patient Outcomes in Adult Medical/Surgical Patients.

Authors:  Morgan A Wynes; Jaclyn A Boyle
Journal:  Innov Pharm       Date:  2021-02-15

2.  Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions.

Authors:  Jincheng Yang; Yu Wang; Kang Liu; Wen Yang; Jianying Zhang
Journal:  Diabetes Ther       Date:  2019-08-19       Impact factor: 2.945

3.  Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia.

Authors:  Susan Storey; Tamryn Fowler Gray; Ashley Leak Bryant
Journal:  Curr Geriatr Rep       Date:  2017-10-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.